Anatomical variation of the sacroiliac joint carries an increased risk for erosion and bone marrow oedema in axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/35532084/

Keep an Eye on the Back: Spondyloarthritis in Patients With Acute Anterior Uveitis (2023)
https://pubmed.ncbi.nlm.nih.gov/35905288/

Deep Learning Detects Changes Indicative of Axial Spondyloarthritis at MRI of Sacroiliac Joints (2023)
https://pubmed.ncbi.nlm.nih.gov/37093751/

Spondyloarthritis, acute anterior uveitis, and Crohn’s disease have both shared and distinct gut microbiota (2023)
https://pubmed.ncbi.nlm.nih.gov/37471465/

Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn’s disease: Clinical and MRI results from a prospective inception cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/35227921/

Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study (2022)
https://pubmed.ncbi.nlm.nih.gov/35368376/

Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/35437900/

The impact of psoriasis on the clinical characteristics, disease burden and treatment patterns of peripheral spondyloarthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35451472/

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35697486/

Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study (2022)
https://pubmed.ncbi.nlm.nih.gov/35922123/

Elucidating the role of a positive family history in differentiating between axial and peripheral spondyloarthritis: an ancillary analysis of the ASAS-PerSpA study (2022)
https://pubmed.ncbi.nlm.nih.gov/34905484/

Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study (2022)
https://pubmed.ncbi.nlm.nih.gov/35922123/

Deep Learning Detects Changes Indicative of Axial Spondyloarthritis at MRI of Sacroiliac Joints (2022)
https://pubmed.ncbi.nlm.nih.gov/35943339/

Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study (2022)
https://pubmed.ncbi.nlm.nih.gov/36003590/

Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study (2022)
https://pubmed.ncbi.nlm.nih.gov/36003590/

Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance (2021)
https://pubmed.ncbi.nlm.nih.gov/33832519/

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33796155/

Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis (2021)
https://pubmed.ncbi.nlm.nih.gov/33693503/

Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/32710108/

Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial (2021)
https://pubmed.ncbi.nlm.nih.gov/34785545/

Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis (2021)
https://pubmed.ncbi.nlm.nih.gov/34187873/

Detection of radiographic sacroiliitis with an artificial neural network in patients with suspicion of axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34363456/

Relation of α 2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/33317138/

Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa (2020)
https://pubmed.ncbi.nlm.nih.gov/32911279/

Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/32447391/

Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31369867/

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept (2019)
https://pubmed.ncbi.nlm.nih.gov/30625261/

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31126334/

Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis? (2017)
https://pubmed.ncbi.nlm.nih.gov/29338611/

Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy (2017)
https://pubmed.ncbi.nlm.nih.gov/28835779/

Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial (2017)
https://pubmed.ncbi.nlm.nih.gov/28601821/